Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

KAIST researchers isolated DDX54 as the master regulator that hinders the effectiveness of immunotherapy—opening a new path ...

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have ...

Immunotherapy is key for triple-negative breast cancer, but a new study finds Black women are receiving it less often than White women.

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...